NDRA Stock — ENDRA Life Sciences Inc

ENDRA Life Sciences Inc (NDRA)

Updated October 16, 2026.

NDRA is a Stock. Total return is -99.9% over the past 9.3 years, 364.0 points behind SPY at 264.1%.

ENDRA Life Sciences Inc. develops thermo-acoustic enhanced ultrasound technology designed to improve clinical diagnostic imaging, with applications in non-alcoholic fatty liver disease, tissue composition analysis, temperature monitoring, vascular imaging, and tissue perfusion analysis. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage medical device technology companies without current income expectations.

NDRA performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 9.3 years, 364.0 points behind SPY at 264.1%. Over the past year its total return — price change plus distributions reinvested — is -32.3%. Its deepest 1-year drawdown was 53.4%.

NDRA key facts

Asset type

Stock

Asset class

Equity

Inception date

06/30/2017

Distribution frequency

None

Last close

$4.74 (as of 2026-10-16)

Market cap

$7,109,583

Average volume

14191.0

Beta

-0.081

Payout ratio

0.0%

EPS

$-5.82

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NDRA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 53.4%.

Who may consider NDRA — and who may not

It is a weaker fit for investors who need monthly cash flow (NDRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NDRA

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions